Changmei Zhang

Dr. Changmei Zhang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
ZCZhong Chen
Zhong Chen
WLWenhua Li
Wenhua Li
LSLiwang Shi
Liwang Shi
LJLei Jiang
Lei Jiang
MLMinghui Li
Minghui Li
HPHaisheng Peng
Haisheng Peng

1 September 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ZCZhong Chen
Zhong Chen
HPHaisheng Peng
Haisheng Peng
CZChangmei Zhang
Changmei Zhang

1 August 2014 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CZChang-Mei Zhang
Chang-Mei Zhang
SYShu-Han Yu
Shu-Han Yu
LZLiang-Shuan Zhang
Liang-Shuan Zhang
ZZZhan-Yi Zhao
Zhan-Yi Zhao
CZChangmei Zhang
Changmei Zhang

29 December 2022 in Drug Delivery
Verified
Journal Article
Open access
CZCongyi Zhang
Congyi Zhang
ZLZehui Liu
Zehui Liu
FWFeng Wang
Feng Wang
BZBin Zhang
Bin Zhang
XZXirui Zhang
Xirui Zhang
CZChangmei Zhang
Changmei Zhang
Hepatocellular carcinoma (HCC) is a malignant tumor leading cancer-associated high mortality worldwide. Unfortunately, the most commonly used drug therapeutics not only lack of target ability and efficiency, but also exhibit severe systemic toxicity to normal tissues. Thus, effective and targeted nanodrug of HCC therapy is emerging as a more important issue. Here, we design and develop the novel nanomicelles, namely Mannose-polyethylene glycol 600-Nitroimidazole (Man-NIT). This micelle compound with high purity comprise two parts, which can self-assemble into nanoscale micelle. The outer shell is selected mannose as hydrophilic moiety, while the inner core is nitroimidazole as hydrophobic moiety. In the cell experiment, Man-NIT was more cellular uptake by HCCLM3 cells due to the mannose modification. Mannose as a kind of glucose transporter 1 (GLUT1) substrate, can specifically recognize and bind to over-expressed GLUT1 on carcinoma cytomembrane. The nitroimidazole moiety of Man-NIT was reduced by the over-expressed nitroreductase with reduced nicotinamide adenine dinucleotide phosphate (NADPH) as the cofactor, resulting in transient deletion of NADPH and glutathione (GSH). The increase of reactive oxygen species (ROS) in HCCLM3 cells disturbed the balance of redox, and finally caused the death of tumor cells. Additional in vivo experiment was conducted using twenty-four male BALB/c nude mice to build the tumor model. The results showed that nanomicelles were accumulated in the liver of mice. The tumor size and pathological features were obviously improved after nanomicelles treatment. It indicates that namomicelles have a tumor inhibition effect, especially Man-NIT, which may be a potential nanodrug of chemotherapeutics for HCC therapy.

1 January 2021 in Drug Delivery
Verified
Journal Article
Open access
WLWenhua Li
Wenhua Li
ZCZhong Chen
Zhong Chen
XLXiaoying Liu
Xiaoying Liu
MLMingming Lian
Mingming Lian
HPHaisheng Peng
Haisheng Peng
CZChangmei Zhang
Changmei Zhang
A novel tumor-targeted glutathione responsive Glycosylated-Camptothecin nanosupramolecular prodrug (CPT-GL NSp) was designed and fabricated via a disulfide bond. The effects of glycoligand with different polarities on solubility, self-assembly, stability, cellular uptake, and glutathione responsive cleaving were explored, and an optimal glycosylated ligand was selected for nanosupramolecular prodrug. It has been found that CPT-GL NSp exhibited higher drug loading than traditional nanoparticles. Among of which maltose modified NSp had the strongest anti-tumor effects than that of glucose and maltotriose. CPT-SS-Maltose had a similar anti-tumor ability to Irinotecan (IR), but the superior performance in solubility, hemolysis, and uptake of HepG2 cells.

18 December 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
CZChangmei Zhang
Changmei Zhang
LYLingyuan Yang
Lingyuan Yang
FWFeng Wang
Feng Wang
MLMingyuan Liu
Mingyuan Liu
ZLZehui Liu
Zehui Liu
LWLijie Wu
Lijie Wu